Extracorporeal immunoadsorption for the specific removal of lipoprotein (a) (Lp(a) apheresis): preliminary clinical data.
The extracorporeal procedure for the specific removal of lipoprotein (a) (Lp(a)) from human plasma--Lp(a) apheresis--was applied to the treatment of three patients with coronary artery disease documented by angiography. Their initial lipid levels were as follows: total cholesterol, 210-230 mg/dl; low-density lipoprotein (LDL) cholesterol, 140-160 mg/dl; Lp(a), 90-120 mg/dl. The patients underwent a total of 168 procedures without significant side effects. Lp(a) apheresis reduced the Lp(a) level by removing up to 88% of Lp(a). Other plasma compounds, including LDL and plasminogen, remained practically unchanged. Lp(a) apheresis appears to be a unique, effective and specific method for lowering the Lp(a) level. Additional trials are needed to evaluate the clinical effect of this treatment.
Pokrovsky
S N
SN
Institute of Experimental Cardiology, Cardiology Research Center, Moscow, Russia.
Sussekov
A V
AV
Afanasieva
O I
OI
Adamova
I Y
IY
Lyakishev
A A
AA
Kukharchuk
V V
VV
D000328:Adult; D001055:Apolipoproteins B / Q000378:metabolism; D001781:Blood Component Removal / Q000379:methods*; D001798:Blood Proteins / Q000378:metabolism; D002784:Cholesterol / Q000097:blood; D003327:Coronary Disease / Q000097:blood / Q000150:complications / Q000628:therapy*; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000150:complications / Q000628:therapy; D007163:Immunosorbent Techniques; D017270:Lipoprotein(a) / Q000097:blood* / Q000302:isolation & purification*; D008297:Male; D008875:Middle Aged; D013997:Time Factors
D001055:Apolipoproteins B; D001798:Blood Proteins; D017270:Lipoprotein(a); D002784:Cholesterol